Abstract
Objectives: Major depressive disorder (MDD) is a serious mental disorder, and there is a great difficulty to diagnose and treat. Hitherto, relatively few studies have explored the correlation between the levels of plasma cell adhesion molecules and MDD.Methods: Thirty outpatients with acute episodes of MDD in Shanghai Mental Health Center and 34 healthy volunteers from the community were recruited as subjects. Protein microarray technology was applied to compared the differences in plasma levels of 17 kinds of adhesion molecular proteins between the two groups. Meanwhile, the diagnostic value of different proteins in depression was discussed by using the receiver operating characteristic curve.Results: The levels of Carcinoembryonic Antigen Related Cell Adhesion Molecule-1(CEACAM-1) and Neural Cell Adhesion Molecule (NrCAM) in MDD patients were significantly higher than those in healthy controls (P < 0.05). The area under ROC curve of CEACAM-1 combined with NrCAM was 0.723, with the sensitivity 0.800 and the specificity 0.676.Conclusion: The plasma levels of CEACAM-1 and NrCAM were significantly up-regulated in MDD, and their combined application was of potential diagnostic value, deserving to expand the sample size for further verification.
Highlights
Major depressive disorder (MDD) is a serious mental disorder with high prevalence rate, recurrence rate and disability rate [1, 2]
We examined the levels of 17 kinds of plasma cell adhesion molecules by protein microarray technology in depressed patients and healthy controls, in order to find out the possible biomarkers for identifying MDD
The results demonstrated that the plasma CEACAM-1 and neural cell adhesion molecules (NrCAM) levels of MDD patients were significantly higher than that of healthy controls
Summary
Major depressive disorder (MDD) is a serious mental disorder with high prevalence rate, recurrence rate and disability rate [1, 2]. According to the World Health Organization (WHO), it has become the leading contributor of disease burden that affects more than 264 million people worldwide (https://www.who.int/news-room/fact-sheets/detail/depression). MDD mainly depends on the clinical manifestations that the patient presents as well as auxiliary application of rating instruments. Clinical symptoms may be dimensional and vary widely, leading to marked heterogeneity [3]. In this context, the absence of objective biological detection methods makes the clinical diagnosis challenging. Exploring the biomarkers related to MDD for the diagnosis is an urgent need
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
